OR WAIT null SECS
April 03, 2024
Article
April 02, 2024
A recap of the biggest FDA news and decisions in cardiovascular medicine from the first 3 months of 2024, with commentary on recent announcements by Deepak Bhatt, MD, MPH, MBA.
Verve Therapeutics announced plans to voluntary pause enrollment of the Heart-1 trial, citing an adverse event and consultation with DSMB, with plans to shift focus to VERVE-102 and Heart-2 trial.
April 01, 2024
This clinical quiz will test your knowledge on management of LDL-C special populations with nonstatin therapies based on the ACC's 2022 expert clinical decision pathway.
March 29, 2024
An analysis of the CLEAR Outcomes trial suggests bempedoic acid was well-tolerated in Hispanic/Latinx and non-Hispanic/Latinx individuals with statin intolerance.
March 27, 2024
A REDUCE-IT analysis highlights consistent cardiovascular benefits with icosapent ethyl across varying levels of Lp(a).
March 26, 2024
Adults with higher triglyceride levels exhibit a higher prevalence of chronic conditions and multi-organ disease.
March 25, 2024
This clinical quiz will test your knowledge on the use of non-statin therapies for LDL-C lowering based on the American College of Cardiology's 2022 Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.
Presence of nephritis in SLE patients is linked to higher cardiovascular risk factors and 3-fold increase in incidence of cardiovascular mortality.
March 24, 2024
A significant association between Lp(a) and adverse cardiovascular outcomes was altered by renal function in patients undergoing percutaneous coronary intervention.